Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept with or without posterior sub-Tenon triamcinolone for macular edema secondary to central retinal vein occlusion
ChiCTR1900021193Phase 4Not yet recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept and triamcinolone acetonide in central retinal vein occlusion (CRVO) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Relief of macular edema and Visual acuity. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
conbercepttriamcinolone acetonide
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on ChiCTR1900021193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021193.